Deana Ferreri, PhD

Phase 3 Trial Suggests Equivalence Between Biosimilar CKD-701 and Reference Ranibizumab in nAMD

January 28, 2023

A phase 3 analysis found that CKD-701, a ranibizumab biosimilar candidate developed by CKD Limited, has comparable clinical efficacy and safety with the reference product (Lucentis) in patients with neovascular age-related macular degeneration (nAMD).

TNF Inhibitor Biosimilar Use in France

December 31, 2022

A study assessing the use of tumor necrosis factor (TNF) alpha inhibitor biosimilars in France found that the biosimilar penetration rate was higher for infliximab compared to etanercept and adalimumab. The authors said they aimed to understand the key drivers for biosimilar use to improve biosimilar uptake in France.

Basaglar Is Not Associated With Lower Out-of-pocket Costs Than the Reference Product

December 24, 2022

The “biosimilar-like” insulin glargine Basaglar was not less expensive for patients than the reference product, Lantus, concluded the authors of a retrospective analysis of commercial pharmacy claims and pharmacy co-payment offsets.

Prescribers’ Perspectives on Strategies for Increasing Biosimilar Adoption

December 17, 2022

Despite recent steps taken by the FDA to streamline approvals and increase availability for biosimilars, biosimilar adoption has been slow and primarily driven by payers in the United States, signaling that more needs to be done to encourage adoption, according to experts at a virtual workshop hosted by the FDA and the University of Maryland.

Biocon’s Biosimilar Insulin Demonstrates PK, PD Equivalence to Humulin

December 03, 2022

The third in a series of clinical studies evaluating pharmacokinetics (PK) and pharmacodynamics (PD) of Biocon’s recombinant human insulins compared to their reference products, found PK and PD equivalence between the biosimilar insulin-70/30 and Humulin-70/30.

VOLTAIRE-X Findings in Patients With Chronic Plaque Psoriasis Supported Interchangeability

November 26, 2022

The VOLTAIRE-X randomized controlled trial determined the adalimumab biosimilar BI 695501 (adalimumab-adbm, Cyltezo; Boehringer Ingelheim) met the FDA’s criteria to be designated as interchangeable with the reference product (Humira).

Administration for Pegfilgrastim Biosimilars Should Minimize Clinic Visits, Consider Patients’ Preferences

November 19, 2022

A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.

Meta-analysis Confirms Biosimilarity Between Bevacizumab Biosimilars, Avastin in NSCLC, Colorectal Cancer

November 12, 2022

The efficacy and safety of bevacizumab biosimilars in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (CRC) is comparable with the reference product (Avastin) and each other, according to a meta-analysis.